Revenues for U.S. cannabis companies are surging, and once Wall Street catches on, stock prices will soar…

The repeal of nearly a century of marijuana prohibition is turning an existing $66 billion black-market into legal sales at an incredible pace.

Recreational use will always have its place, but it’s the true healing power of medical cannabis and CBD that is a huge driver for propelling the industry forward. Everyone from state officials to entire communities are starting to view medical cannabis as a way to fight the opioid epidemic, which contributed to more than 70,000 deaths in 2017.

Put all these growth drivers together and the legal cannabis market will move from its current base of $20 billion in U.S. revenues to well past the $100 billion level.

Just to keep pace with the demand for legal marijuana and the creation of new markets for cannabis, more product will need to hit the shelves. In fact, industry revenues will need to speed forward at over 80% per year.

At this point, you know that it’s not a matter of “if” but “when” cannabis goes fully legally, and it’s why one prominent figure has gone all in on cannabis.

With that kind of growth, you’ll be looking at a market nearly 20x its current size in just five years.

And given the way cannabis sales are rolling in, you’ll see why cannabis companies are right on the cusp of $1 trillion surge in value…

Doubling Sales Every Few Months

In the latest reporting period, there were 28 U.S. companies with revenues greater than $5 million over the prior quarter.

For those companies alone, sales shot up 47.5% over just three months. Now, growth like that compounds incredibly well and, at this rate, we can expect sales for these market leaders to blast past $2 billion per quarter by year end – or over $8 billion per year.

Just look at Green Thumb Industries (CSE: GTII, OTC: GTBIF). It posted sales of $27.9 million last quarter, which was up from $20.8 million for the prior three months. That’s a growth rate of over 200% per year.

For Harvest Health and Recreation (CSE: HARV, OTC: HRVSF), its $19.2 million in sales are increasing at a 500% annualized clip. And for Acreage Holdings (CSE: ACRG, OTC: ACRGF) – whose prominent board member was once “unalterably opposed” to cannabis legalization – sales grew 92% in just three months.

This one-of-a-kind cannabis investing tool puts the power to profit directly in your hands. To learn how to get immediate access, just click here.

Even cannabis companies that have some of the lowest ratings possible within our NICILytics database are managing to grow their top-lines at over 80% every three months. Once you read what we have to say about their management teams in our analyst reports, you’ll want to steer clear of buying their stock.

But the point is the amount of growth just proves how much demand there is out there for cannabis products – and this industry is just getting started.

That’s why it’s so important now to pick your spots – not own stock in just any cannabis company.

Top of the List Cannabis Stocks

One of the latest additions to the Cannabis Investor’s Report model portfolio is bringing in more sales – and generating more profits – than any other multi-state operator.

For The Cannabis IPO Insider, a core holding could see sales 236% higher a year from now as it has beachheads in the latest state to legalize.

It’s continued results like these that will drive cannabis stocks to levels that will mint an entire new class of marijuana millionaires from investors getting in on the ground floor now.

Outside of the picks in our portfolios, if you’re just getting started with cannabis investing, we wanted to make sure you saw our free premium guide on three hot pot stocks.

For the moment, cannabis stocks are still considered taboo by many. That’s because Wall Street and large institutional investors have yet to make any meaningful moves into cannabis. And slower growing, cash rich institutions are still mostly sitting on the sidelines.

But these players are looking hard at how to play the biggest investment surge since the internet and, when they do, we’ll be looking at a $1 trillion market virtually overnight.

By making moves now, you are truly an early adopter.

Greg Miller
Executive Director, National Institute for Cannabis Investors

P.S. One landmark event last year has analysts predicting sales in the hemp CBD market will skyrocket to $22 billion by 2022. That’s a jump of 3,622% in fewer than three years. With predictions like these, there’s no better time than right now to get involved with CBD companies. Our experts have identified two companies that you don’t want to miss out on. For more information, just click here.


Comments

One response to “Revenue Jumps at Two U.S. Cannabis Plays Is Big Time Bait for Wall Street”

  1. I am interested in your opinion on why Acreage is trading at such a low price compared to what the deal with Canopy would indicate. By my calculations Acreage should be trading at about $26 ($2.55 cash payment plus .58 share of Canopy) — yet it is stuck around $18. I realize there is no guarantee the deal will go through, but that is still a large discount. And Acreage is not a bad play in its own right. The one piece of information I haven’t seen is what date has been set for when you have to own Acreage stock in order to receive the benefit of the Canopy deal. Is it too late? Thanks for any info or thoughts.

Leave a Reply

Your email address will not be published. Required fields are marked *